Comparison Between Preoperative Vaginal and Postoperative Sublingual Misoprostol for Prevention of Postpartum Hemorrhage During Cesarean Section

Launched by ASSIUT UNIVERSITY · Jan 3, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating the best way to use a medication called misoprostol to prevent severe bleeding after a cesarean section (C-section). The trial will compare giving misoprostol before the surgery (through the vagina) versus after the surgery (under the tongue). Severe bleeding after childbirth, known as primary postpartum hemorrhage, is a serious condition that can happen during or after a C-section and can lead to complications for the mother.

To participate in this study, women must be scheduled for an elective C-section at 37 weeks of pregnancy or later and have a normal fetal heart rate. However, those with certain conditions—like placenta previa (where the placenta is too low), high blood pressure during pregnancy, or a history of severe bleeding after childbirth—won’t be eligible. Participants will receive misoprostol as part of their care and will be monitored for any effects, helping researchers understand the best timing for the medication to reduce bleeding. This research is important for improving safety during childbirth, especially as the number of C-sections continues to rise.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The study includes women will undergo elective lower segment CS at term (≥37 weeks) with normal fetal heart tracing
• Exclusion Criteria:
• • Women with placenta previa . preterm delivery, hypertensive disorders of pregnancy, bleeding tendency, previous history of PPH, concurrent anticoagulant therapy, concurrent long-term use of steroids, fetal distress and antepartum haemorrhage will be excluded from the study